
Lonza

Amaxa[™] 4D-Nucleofector[™] Protocol for K562 [ATCC[®]] For 4D-Nucleofector[™] X Unit

Human chronic myelogenous leukemia cell line; lymphoblastoid cells; [ATCC[®] CCL-243[™], cryopreserved]

Example for Nucleofection™ of K562 cells

Transfection efficiency of K562 cells 24 hours post Nucleofection[™]. K562 cells (ATCC[®] CCL-243[™]) were transfected with program FF-120 and 0.4 µg of pmaxGFP[™] Vector in 20 µl Nucleovette[™] Strips. 24 hours post Nucleofection[™] cells were analyzed on a FACSCalibur[™] [Becton Dickinson]. Cell viability (%PI negative cells) is usually around 95% after 24 hours.



Product Description

Recommended Kit(s)-SF Cell Line 4D-Nucleofector™ X Kit

| Cat. No. | V4XC-2012 | V4XC-2024 | V4XC-2032 |
|--|--|---------------------------------------|---|
| Transfection volume | 100 µl | 100 µl | 20 µl |
| Size [reaction] | 2 x 6 | 24 | 2 x 16 |
| Nucleofector [™] Solution | 2 x 0.675 ml (0.492 ml + 27 % overfill) | 2.25 ml [1.968 ml + 13 % overfill] | 0.675 ml _(0.525 ml + 22 % overfill) |
| Supplement | 2 x 0.15 ml (0.108 ml + 27 % overfill) | 0.5 ml (0.432 ml + 13 % overfill) | 0.15 ml _(0.115 ml + 22 % overfill) |
| pmaxGFP™ Vector (1 µg/µl in 10 mM Tris pH 8.0) | 50 µg | 50 µg | _50 μg |
| Single Nucleocuvette™ (100 µl) | 12 | 24 | |
| 16-well Nucleocuvette™ Strips (20 µI) | - | - | 2 |

Storage and stability

Note

Store Nucleofector[™] Solution, Supplement and pmaxGFP[™] Vector at 4 °C. For long-term storage, pmaxGFP[™] Vector is ideally stored at -20 °C. The expiration date is printed on the solution box. Once the Nucleofector[™] Supplement is added to the Nucleofector[™] Solution, it is stable for three months at 4 °C. 4D-Nucleofector[™] Solutions can only be used with Nucleocuvettes[™] (conductive polymer cuvettes), i.e. in the 4D-Nucleofector[™] System and the 96-well Shuttle[™] Device. They are not compatible with the Nucleofector[™] II/2b Device.

Required Material

Note

Please make sure that the entire supplement is added to the Nucleofector[>] Solution. The ratio of Nucleofector[>] Solution to supplement is 4.5:1 (see table 1)

- 4D-Nucleofector[™] System (4D-Nucleofector[™] Core Unit and 4D-Nucleofector[™] X Unit)
- Supplemented 4D-Nucleofector™ Solution at room temperature
- Supplied 100 µl single Nucleocuvette™ or 20 µl 16-well Nucleocuvette™ Strips
- Compatible tips for 20 µl Nucleocuvette[™] Strips: epT.I.P.S. [US/CDN: Eppendorf North America, Cat. No. 2491.431, Rest of World: Eppendorf AG, Cat. No. 0030073.266], Matrix TallTips[®] [Matrix Technologies Corp., Cat. No. 7281] or LTS Tips [Rainin Instruments, LLC, Cat. No. SR-L10F, SR/SS-L250S, SR/SS-L300S]. Before using other types of pipette tips, please ensure they reach the bottom of the Nucleocuvette[™] Wells without getting stuck
- Supplied pmaxGFP™ Vector, stock solution 1µg/µl

Note

For positive control using pmaxGFP^m, dilute the stock solution to an appropriate working concentration. Further details are provided in table 3 of this Optimized Protocol. The volume of substrate solution added to each sample should not exceed 10% of the total reaction volume (2 μ l for 20 μ l reactions; 10 μ l for 100 μ l reactions).

- Substrate of interest, highly purified, preferably by using endotoxinfree kits; A260:A280 ratio should be at least 1.8
- Cell culture plates of your choice
- Culture medium: Iscove's modified Dulbecco's medium with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 90% [ATCC[®], Cat. No. 30-2005]; fetal bovine serum, 10%
- Prewarm appropriate volume of culture medium to 37 °C (see table 2)
- Appropriate number of cells/sample (see table 2)

1. Pre Nucleofection™

- 1.1 Replace media every 2–3 days
- 1.2 Passage cells after reaching 1 x 10⁶ cells/ml. Do not use cells after passage 10 for Nucleofection[™]
- 1.3 Seed out 1 x 10⁵ cells/ml
- Subculture 2 days before Nucleofection™ at a density of 3 x 10⁵cells/ml. Higher cell densities may cause lower Nucleofection™ Efficiencies

2. Nucleofection[™]

For Nucleofection™ Sample contents and recommended Nucleofector™ Program, please refer to Table 3.

- 2.1 Please make sure that the entire supplement is added to the Nucleofector[™] Solution
- 2.2 Start 4D-Nucleofector[™] System and create or upload experimental parameter file (for details see device manual)
- 2.3 Select/Check for the appropriate Nucleofector™ Program (see table3)
- Prepare cell culture plates by filling appropriate number of wells with desired volume of recommended culture media (see table 4) and pre-incubate/equilibrate plates in a humidified 37 °C/5 % CO₂ incubator
- 2.5 Pre-warm an aliquot of culture medium to 37 °C (see table 4)
- 2.6 Prepare plasmid DNA or pmaxGFP[™] Vector or siRNA (see table 3)
- 2.7 Count an aliquot of the cells and determine cell density
- 2.8 Centrifuge the required number of cells (see table 3) at 90xg for 10 minutes at room temperature. Remove supernatant completely
- 2.9 Resuspend the cell pellet carefully in room temperature 4D-Nucleofector[™] Solution (see table 3)
- 2.10 Prepare mastermixes by dividing cell suspension according to number of substrates
- 2.11 Add required amount of substrates to each aliquot (max. 10% of final sample volume)
- 2.12 Transfer mastermixes into the Nucleocuvette™ Vessels

Note

As leaving cells in Nucleofector[™] Solution for extended periods of time may lead to reduced transfection efficiency and viability it is important to work as quickly as possible. Avoid air bubbles while pipetting.

- 2.13 Gently tap the Nucleocuvette[™] Vessels to make sure the sample covers the bottom of the cuvette
- 2.14 Place Nucleocuvette[™] Vessel with closed lid into the retainer of the 4D-Nucleofector[™] X Unit. Check for proper orientation of the Nucleocuvette[™] Vessel
- 2.15 Start Nucleofection™ Process by pressing the "Start" on the display of the 4D-Nucleofector™ Core Unit (for details, please refer to the device manual)
- 2.16 After run completion, carefully remove the Nucleocuvette[™] Vessel from the retainer
- 2.17 Incubate Nucleocuvette™ 10 minutes at room temperature
- 2.18 Resuspend cells with pre-warmed medium (for recommended volumes see table 5). Mix cells by gently pipetting up and down two to three times. When working with the 100 µl Nucleocuvette™ use the supplied pipettes and avoid repeated aspiration of the sample
- 2.19 Plate desired amount of cells in culture system of your choice (for recommended volumes see table 5)

3. Post Nucleofection™

3.1 Incubate the cells in humidified 37 $^{\circ}$ C/5 % CO₂ incubator until analysis. Gene expression or down regulation, respectively, is often detectable after only 4–8 hours

Additional Information

For an up-to-date list of all Nucleofector[™] References, please refer to: www.lonza.com/nucleofection-citations

For more technical assistance, contact our Scientific Support Team:

USA /Canada

Phone:800 521 0390 (toll-free)Fax:301 845 8338E-mail:scientific.support@lonza.com

Europe and Rest of World

| Phone: | +49 221 99199 400 |
|---------|---------------------------------|
| Fax: | +49 221 99199 499 |
| E-mail: | scientific.support.eu@lonza.com |

Lonza Cologne GmbH 50829 Cologne, Germany

Please note that the Amaxa" Nucleofector" Technology is not intended to be used for diagnostic purposes or for testing or treatment in humans.

The Nucleofector[™] Technology, comprising Nucleofection[™] Process, Nucleofector[™] Device, Nucleofector[™] Solutions, Nucleofector[™] 96-well Shuttle[™] System and 96-well Nucleocuvette[™] plates and modules is covered by patent and/or patent-pending rights owned by Lonza Cologne GmbH.

Amaxa, Nucleofector, Nucleofection, 4D-Nucleofector, Nucleocuvette and maxGFP are registered trademarks of the Lonza Cologne GmbH in Germany and/or U.S. and/or other countries.

ATCC[®] and the ATCC Catalog Marks are trademarks of ATCC.

Other product and company names mentioned herein are the trademarks of their respective owners.

This kit contains a proprietary nucleic acid coding for a proprietary copepod fluorescent protein intended to be used as a positive control with this Lonza product only. Any use of the proprietary nucleic acid or protein other than as a positive control with this Lonza product is strictly prohibited. USE IN ANY OTHER APPLICATION REQUIRES A LICENSE FROM EVROGEN. To obtain such a license, please contact Evrogen at license@evrogen.com.

The CMV promoter is covered under U.S. Patents 5,168,062 and 5,385,839 and its use is permitted for research purposes only. Any other use of the CMV promoter requires a license from the University of Iowa Research Foundation, 214 Technology Innovation Center, Iowa City, IA 52242.

The use of this product in conjunction with materials or methods of third parties may require a license by a third party. User shall be fully responsible for determining whether and from which third party it requires such license and for the obtainment of such license.

No statement is intended or should be construed as a recommendation to infringe any existing patent.

© Copyright 2010, Lonza Cologne GmbH. All rights reserved.

Table 1: Volumes required for a single reaction

| | 100 µl Single Nucleocuvette™ | 20 µl Nucleocuvette™ Strip |
|----------------------------------|------------------------------|----------------------------|
| Volume of Nucleofector™ Solution | 82 µl | 16.4 µl |
| Volume of Supplement | 18 µl | 3.6 µl |

Table 2: Required amounts of cells and media for Nucleofection™

| | _100 µl Single Nucleocuvette™ | 20 µl Nucleocuvette™ Strip |
|---|---|--|
| Culture medium per sample post Nucleofection™ (for transfer and culture) | 2 ml | 230 µl |
| Cell number per Nucleofection™ Sample | 1 x 10 ⁶ (Lower or higher cell numbers may influence transfection results) | 2×10^5 (2.5 x 10^3 cells can be used with slightly re- duced viability. At even lower cell numbers viability is strongly decreased) |

Table 3: Contents of one Nucleofection™ Sample and recommended program

| | | 100 µl Single Nucleocuvette™ | 20 µl Nucleocuvette™ Strip |
|------------------------------|---|--------------------------------------|---------------------------------------|
| Cells | | 1 x 10 ⁶ | 2 x 10 ⁵ |
| Substrate* | pmaxGFP™ Vector | 2 µg | 0.4 µg |
| or | plasmid DNA (in H ₂ 0 or TE) | 2 µg | 0.2–1 µg |
| or | siRNA | 30–300nM siRNA (3–30 pmol/sample) | 30–300nM siRNA (0.6–6 pmol/sample) |
| SF Cell Line 4D-Nucle | ofector™ X Solution | 100 µl | 20 µl |
| Program | | FF-120 | FF-120 |
| * Volume of substrate should | comprise maximum 10 % of total reaction v | rolume | |

Table 4: Culture volumes required for post Nucleofection™ Steps

| | 100 µl Single Nucleocuvette™ | 20 µl Nucleocuvette™ Strip* | |
|---|------------------------------|-----------------------------|--|
| 12 -well culture plate | 1.5 ml | | |
| 96-well culture plate | | 150 µl | |
| Culture medium to be added to the sample post Nucleofection™ | 500 µl | 14 08 | |
| * Maximum cuvette volume 200 μl | | | |

Table 5: Recommended volumes for sample transfer into culture plate

| | 100 μl Single Nucleocuvette™ | 20 μl Nucleocuvette™ Strip* |
|---|---|-----------------------------|
| Culture medium to be added to the sample post Nucleofection™ | 500 µl | 80 µl |
| Volume of sample transferred to culture plate | complete sample (use supplied pipettes) | 50 μl |
| * Maximum cuvette volume 200 µl | | |